<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02899091</url>
  </required_header>
  <id_info>
    <org_study_id>CHA-PAD-101</org_study_id>
    <nct_id>NCT02899091</nct_id>
  </id_info>
  <brief_title>Evaluation of the Safety and Potential Therapeutic Effects After Intravenous Transplantation of CB-AC-02 in Patients With Alzheimer's Disease</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Phase I / IIa Clinical Trial for Evaluation of Safety and Potential Therapeutic Effect After Transplantation of CB-AC-02 in Patients With Alzheimer's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CHABiotech CO., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CHABiotech CO., Ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the study is to evaluate the safety and the potential therapeutic effects of
      CB-AC-02 Intravenous Transplantation in patients with Alzheimer' disease comprised of 2
      treatment cohorts:
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>September 2016</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Anticipated">March 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Adverse Events</measure>
    <time_frame>48 weeks</time_frame>
    <description>Number of subjects with treatment-related adverse events.
The safety and tolerability of treatment with CB-AC-02 will be assessed by analysis of adverse events, abnormal findings on physical examinations, standard laboratory tests.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes from the baseline in ADAS-Cog (Azheimer's disease Assessment Scale - Congintive Subscale) Score</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from the baseline in K-MMSE (Korean-Mini Mental Status Examination) Score</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from the baseline in GDS (Global Deterioration Scale)</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from the baseline in CDR (Clinical Dementia Rating) Score</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from the baseline in K-IADL (Korean Instrumental Activities of Daily Living) Score</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from the baseline in CGA-NPI (Caregiver Administered-Neuropsychiatric Inventory) Score</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in CIBIC (Clinician Interview Based Impression of Change)-plus</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from the baseline in SF-36</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Amyloid Beta and Tau amount (pg/mL) in CSF (Cerebrospinal fluid)</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Brain MRI (Magnetic Responance imaging)</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from the baseline of CMRglc (cerebral metabolic rate for glucose ) analyzed with SPM (statistical parametric mapping) with Brain FDG PET imaging</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from the baseline of Amyloid amount analyzed with SPM (statistical parametric mapping) with amyloid PET imaging</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of band power in qEEG (Quantitative electroencephalography)</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Alzheimer's Disease</condition>
  <arm_group>
    <arm_group_label>CB-AC-02</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with Alzheimer's disease Intervention: CB-AC-02</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects with Alzheimer's disease Intervention: Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CB-AC-02</intervention_name>
    <description>Stage1:
① Group1: CB-AC-02, 2.0 x 10^8 cells on day 0
② Group2: CB-AC-02, 2.0 x 10^8 cells, on day 0 and on week 4 (repeated injection)
Stage2
① Arm1: K-MMSE 20~26 CB-AC-02, 2.0 x 10^8 cells on day 0 and on week 4 (repeated injection)
② Arm2: K-MMSE 10~19 CB-AC-02, 2.0 x 10^8 cells on day 0 and on week 4 (repeated injection)</description>
    <arm_group_label>CB-AC-02</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Stage2:
Placebo on day 0 and on week 4 (repeated injection)</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Korean male or female at 50+ years of age at the time of screening visit

          2. Diagnosis of Probable Alzheimer disease (probable AD) according to NINCDS-ADRDA
             criteria at Screening visit

          3. Positive for Amyloid on amyloid-ligand PET

          4. A subject with the imaging findings of Alzheimer's disease as confirmed by MRI or PET

               -  Presence of brain atrophy on brain MRI by visual assessment

               -  Presence of reduced brain glucose metabolism in bilateral temporal-parietal lobe
                  on FDG-PET

          5. Korea Mini-Mental State Examination (KMMSE) score of 10-26 at time of screening visit

          6. Presence of caregiver who can provide information on the subject's condition

          7. Subject who has been taking stable dose of Alzheimer medication for last 2 months or
             more

          8. Subject who is informed of the clinical trial and signs a consent form (if unable to
             sign, a consent from a legally acceptable representative is required)

        Exclusion Criteria:

          1. Concurrent Dementia as a result of other disorders [i.e. infectious disease of the
             central nervous system such as HIV, syphilis, head injury, Creutzfeld-Jacob disease,
             Picks disease, Huntington's disease, Parkinson's disease, other subdural hematoma,
             hydrocephalus and structural brain lesions, drug addiction, alcoholism, substance
             abuse, thyroid disease, parathyroid disease, vitamins and other nutritional
             deficiencies and vascular etc.]

          2. Subject with vascular dementia as determined by the clinical criteria of DSM-IV and
             the imaging criteria of Erkinkuntii

          3. Subject with severe white matter hyperintensities (i.e. ≥ 25mm of the deep white
             matter and ≥ 10mm of the periventricular capping/banding in lengths)

          4. Abnormal laboratory findings at screening visit:

             A. ALT or AST ≥ 2.5 times the upper limit of normal value

             B. Serum creatinine ≥ 1.5 times the upper limit of normal value

             C. Total bilirubin ≥ 2 times the upper limit of normal value

             D. Total WBC counts &lt; 3,000/㎣

             E. Hemoglobin &lt;9.5g/dL in men or &lt;9.0g/dL in women

             F. Platelet count &lt; 150,000/㎣ at screening visit

             G. PT (INR) ≥ 1.5 or aPTT ≥ 1.5 times the upper limit of normal value

          5. Subjects who are positive for HIV, syphilis or active HBV, HCV infection

          6. Subjects in poor medical condition or subjects with severe cardiovascular,
             gastrointestinal, pulmonary or endocrinologic disease A. Suspected active active lung
             disease on chest X-ray at screening visit B. Diagnosis of cancer (except for the
             subjects who remains in complete remission for 5 years or more )

          7. Subject with concurrent unstable psychiatric disorder (i.e. severe depression, or
             schizophrenia, or bipolar disorder, etc)

          8. Pregnant or lactating women

          9. Women of childbearing age who reject to practice contraception with one of the
             following methods

               -  Use a condom

               -  Use of contraceptive (oral, dermal, or injectable)

               -  Use an intra-uterine contraceptive device

         10. Subjects with a history of alcohol abuse (&gt;30g/day) or drug abuse

         11. Subjects who cannot undergo any of the tests performed in this clinical trial (for
             example, MRI, CT, PET, CSF study)

         12. Subjects with known allergies to protein products (Bovine serum), antibiotics
             (gentamycin) or DMSO

         13. Subjects whom the principal investigator considers inappropriate for participation in
             theis study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Hye Sun Kim</last_name>
    <phone>+82-31-881-7431</phone>
    <email>goldfish79@chamc.co.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Bundang Medical Center</name>
      <address>
        <city>Seongnam-si</city>
        <state>Gyeonggi-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>HyunSook Kim, MD, PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 2, 2016</study_first_submitted>
  <study_first_submitted_qc>September 12, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 14, 2016</study_first_posted>
  <last_update_submitted>September 12, 2016</last_update_submitted>
  <last_update_submitted_qc>September 12, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 14, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Alzheimer's disease</keyword>
  <keyword>Mesenchymal Stem cells</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

